Disse symptomer synes at forekomme hyppigst i begyndelsen af behandlingsperioden og at aftage i hyppighed og styrke ved fortsat behandling.
These symptoms tend to be most prominent at the initiation of therapy and decrease in frequency and severity with continued treatment.